Oruka Therapeutics, Inc.

ORKA · Nasdaq · SIC 2834: Pharmaceutical Preparations
399
SEC Filings

Business Summary

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead program, ORKA-001, targets IL-23p19 with extended half-life YTE technology for infrequent dosing, and its co-lead program, ORKA-002, targets IL-17A/F for psoriasis, hidradenitis suppurativa, psoriatic arthritis, and other conditions. The company was formed through the merger of ARCA biopharma and Pre-Merger Oruka Therapeutics in August 2024.

Next Earnings

Q2 FY2026 — expected 2026-09-17

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionORKAdiscussed_in_filing Cybersecurity
topic_mentionORKAdiscussed_in_filing Trusted Computing
topic_mentionORKAdiscussed_in_filing Blockchain & Crypto
topic_mentionORKAdiscussed_in_filing Regulation
topic_mentionORKAdiscussed_in_filing Healthcare & Bio
topic_mentionORKAdiscussed_in_filing AI Compute
topic_mentionORKAdiscussed_in_filing Cybersecurity
topic_mentionORKAdiscussed_in_filing Trusted Computing
topic_mentionORKAdiscussed_in_filing Blockchain & Crypto
topic_mentionORKAdiscussed_in_filing Regulation
topic_mentionORKAdiscussed_in_filing Healthcare & Bio
topic_mentionORKAdiscussed_in_filing AI Compute
topic_mentionORKAdiscussed_in_filing Cybersecurity
topic_mentionORKAdiscussed_in_filing Trusted Computing
topic_mentionORKAdiscussed_in_filing Blockchain & Crypto
topic_mentionORKAdiscussed_in_filing Regulation
topic_mentionORKAdiscussed_in_filing Healthcare & Bio
topic_mentionORKAdiscussed_in_filing AI Compute
topic_mentionORKAdiscussed_in_filing Cybersecurity
topic_mentionORKAdiscussed_in_filing Trusted Computing

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001213900-26-026929EDGAR88K words
2025-03-062024-12-310001213900-25-021165EDGAR—
2024-02-012023-12-310000950170-24-009809EDGAR—
2023-02-242022-12-310000950170-23-004379EDGAR—
2022-03-142021-12-310001564590-22-010075EDGAR—
2021-03-182020-12-310001564590-21-014148EDGAR—
2020-02-182019-12-310001564590-20-005032EDGAR—
2019-02-272018-12-310001564590-19-004882EDGAR—
2018-03-222017-12-310001564590-18-006566EDGAR—
2017-03-212016-12-310001564590-17-004897EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001213900-25-109182EDGAR53K words
2025-08-112025-06-300001213900-25-074281EDGAR—
2025-05-142025-03-310001213900-25-043279EDGAR—
2024-11-132024-09-300001213900-24-097443EDGAR—
2024-08-012024-06-300000950170-24-089246EDGAR—
2024-04-252024-03-310000950170-24-048329EDGAR—
2023-10-182023-09-300000950170-23-053972EDGAR—
2023-07-212023-06-300000950170-23-033834EDGAR—
2023-04-242023-03-310000950170-23-014091EDGAR—
2022-10-282022-09-300001564590-22-035668EDGAR—
2022-08-022022-06-300001564590-22-027468EDGAR—
2022-05-022022-03-310001564590-22-017043EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2025-12-110001213900-25-120676EDGAR1K words
2025-09-220001213900-25-090129EDGAR—
2025-07-010001213900-25-060352EDGAR—
2025-06-030001213900-25-050756EDGAR—
2025-02-050001213900-25-010525EDGAR—
2024-12-190001213900-24-110303EDGAR—
2024-11-180001213900-24-099645EDGAR—
2024-11-140001213900-24-098530EDGAR—
2024-10-040001213900-24-085543EDGAR—
2024-09-130001213900-24-078549EDGAR—

399 total filings indexed. 367 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

psoriasis hidradenitis-suppurativa psoriatic-arthritis inflammatory-and-immunology axial-spondyloarthritis yte-half-life-extension-technology fragment-crystallizable-(fc)-domain-modification neonatal-fc-receptor-(fcrn)-ph-dependent-binding

Company Identity

CIK0000907654
TickerORKA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: f50d0d6e06d6b1ad8cda6688264ca2afbc37b0851addb221202b01ccfbdfcfcc
parent: 6d96ee1e5756708283ceeded8d43aeea310e58eddb5c8c488d977dc89028fb25
content hash: 2e85378cfb7a1cbb2986de147f503c7b9411c6a4e77d8291dd1b8ec34fe4691c
signed: 2026-04-13T04:46:45.490Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf